Preliminary data presented on March 28 as a late-breaking abstract at the American College of Cardiology's 58th annual scientific session from the largest CD34+ adult stem cell study for heart disease has shown the first evidence that delivering a potent form of autologous (from the patient) adult stem cells into the heart muscle of patients with severe angina may result in less pain and improved exercise tolerance.
The six-month, Phase II data were presented by principal investigator Douglas Losordo, M.D., director of the Feinberg Cardiovascular Research Institute and of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. The trial was sponsored by Baxter International Inc.
"The results from this study provide the first evidence that a patient's own stem cells could actually be used as a treatment for their heart disease," said Losordo, who also is the Eileen M. Foell Professor of Heart Research at the Feinberg School. "The study provides potential hope for those patients with currently untreatable angina to be more active with less pain."
"Baxter sponsored this trial in order to continue advancing the science of adult stem cell therapies for cardiovascular disease," said Hartmut J. Ehrlich, MD, vice president of global research and development for Baxter's BioScience business. "While the preliminary results from this early- stage trial seem encouraging, further studies will be necessary to evaluate the effectiveness of this adult stem cell therapy."
Losordo also cautioned that the findings of the 26-site trial, while encouraging, are not yet definitive and require verification in a larger study. Northwestern Memorial Hospital was the lead site of the study.
This prospective, randomized, double-blind, placebo-controlled, multi-center study included 167 adult patients who were on maximal medical therapy and were not suitable candidates for conventional procedures to improve blood flow to the heart, such as angioplasty, stents, or coronary artery bypass surgery.
All patients were given a drug to stimulate release of CD34+ adult stem cells from the bone marrow, and these cells were then collected from the bloodstream using a process called apheresis. The CD34+ cells were then separated from the other blood components for use in this investigational therapy using Baxter's ISOLEX 300i Magnetic Cell Selection System, currently approved for use with cancer patients.
The CD34+ adult stem cells were injected into 10 locations in the heart muscle of patients in the treatment group. Patients in the placebo group received saline. A sophisticated electromechanical mapping technology identified where the heart muscle was alive but not functioning, because it was not receiving enough blood supply. This state is called hibernating myocardium.
"Muscle hibernates because it wants to decrease energy consumption to stay alive," Losordo explained. "It's not getting enough oxygenated blood to perform normally, so it shuts down its contractile function."
The autologous stem cell transplant is the first therapy to produce an improvement in patients with severe angina, measured by their ability to walk on a treadmill. Six months after the procedure, the autologous stem cell transplant patients were able to walk longer (average of 60 seconds) on a treadmill than the placebo group. It also took longer until they experienced angina pain on a treadmill compared to the placebo group and, when they felt pain, it went away faster with rest. In addition, they had a reduction of episodes of chest pain compared to the control group.
Out of the estimated one million people in the U.S. who suffer from chronic, severe angina -- chest pain due to blocked arteries -- about 300,000 cannot be helped by any traditional medical treatment such as angioplasty, bypass surgery or stents. This is called intractable angina, the severity of which is designated by classes.
The patients in the Baxter-sponsored study were Canadian Classification System (CCS) class 3 or 4, meaning they had chest pain from normal to minimal activities such as brushing their teeth or even resting.
Losordo was previously a paid consultant to Baxter.
Marla Paul | EurekAlert!
“Pregnant” Housefly Males Demonstrate the Evolution of Sex Determination
23.05.2017 | Universität Zürich
Scientists enlist engineered protein to battle the MERS virus
22.05.2017 | University of Toronto
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.
In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...
Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...
23.05.2017 | Event News
22.05.2017 | Event News
17.05.2017 | Event News
23.05.2017 | Physics and Astronomy
23.05.2017 | Life Sciences
23.05.2017 | Event News